Cardiovascular disease is the most prevalent class of diseases in the world; more individuals die from heart diseases than any other illness. Despite current and past efforts, diagnosis and treatment options are limited. The underlying molecular mechanisms that lead to the onset and progression of detrimental phenotypes in the heart remain largely elusive. To battle against the ever-increasing number of cardiovascular disease-related deaths, major goals of the HUPO Cardiovascular Initiative include the development and utilization of cutting-edge proteomics technologies to map the dynamic cardiac and vascular proteomes, elucidate cardiovascular disease mechanisms, identify candidate therapeutic targets, and provide clinically useful diagnosis as well as risk prediction. Current emphasis is given to promoting the development and adoption of quantitative protein assays targeting highly relevant cardiovascular proteins, such that translation of proteomics technologies may be expedited.
Current lines of work:
Papers:Parker SJ, Venkatraman V, Van Eyk JE. Effect of peptide assay library size and composition in targeted data-independent acquisition-MS analyses. Proteomics. 2016 Aug;16(15-16):2221-37. doi: 10.1002/pmic.201600007.
Lam MP, Venkatraman V, Cao Q, Wang D, Dincer TU, Lau E, Su AI, Xing Y, Ge J, Ping P, Van Eyk JE. Prioritizing Proteomics Assay Development for Clinical Translation. J Am Coll Cardiol. 2015 Jul 14;66(2):202-4.
Semba RD, Lam M, Sun K, Zhang P, Schaumberg DA, Ferrucci L, Ping P, Van Eyk JE. Priorities and trends in the study of proteins in eye research, 1924-2014. Proteomics Clin Appl. 2015 Dec;9(11-12):1105-22. doi: 10.1002/prca.201500006.
Fert-Bober J, Giles JT, Holewinski RJ, Kirk JA, Uhrigshardt H, Crowgey EL, Andrade F, Bingham CO 3rd, Park JK, Halushka MK, Kass DA, Bathon JM, Van Eyk JE. Citrullination of myofilament proteins in heart failure. Cardiovasc Res. 2015 Nov 1;108(2):232-42.
For more information or participation opportunities please contact office(at)hupo.org.